Dosage Forms & Drug Delivery Systems – Page 57

Cascade Impactor Setup Error at stability pull: FDA/MHRA investigation and corrective actions

Identifying symptoms or signals indicating a cascade impactor setup error can prevent significant downstream effects. Symptoms often manifest in various forms:Click to read the full article.

E&L Failure in MDI assembly: E&L risk assessment and documentation

Symptoms of E&L failures may manifest during routine analysis, investigations, or post-production quality control checks. Key indicators of potential E&L issues include:Click to read the full article.

Cascade Impactor Setup Error after device supplier change: FDA/MHRA investigation and corrective actions

The first step in any investigation is to identify and document the symptoms or signals that prompted the need for further scrutiny. For a cascade impactor setup error after a…

Apsd Oos during method transfer: method variability vs true product failure assessment

When investigating APSD OOS results during method transfer, the first step is identifying the symptoms or signals that indicate a potential problem. Key signals might include:Click to read the full…

Delivered Dose Uniformity Failure during method transfer: device qualification and assembly controls

Understanding the trigger points for investigating delivered dose uniformity failures is paramount. Symptoms may vary but often manifest in the following ways:Click to read the full article.

Residual Solvent Oos in transdermal patch manufacturing: process parameter review and validation impact

Identifying early signals of potential OOS results is crucial for timely intervention. Symptoms that signal issues with residual solvents may include:Click to read the full article.

Coating Weight Variability in transdermal patch manufacturing: inspection-ready documentation pack

Coating weight variability may manifest in several observable symptoms during the manufacturing process, including:Click to read the full article.

Packaging Dry-Out after backing material change: GMP investigation plan and CAPA

Detection of packaging dry-out manifests as a variety of physical signs that often originate from either manufacturing or quality control processes. Symptoms may include the following:Click to read the full…

Backing Delamination during lamination: packaging integrity and shelf-life justification

Identifying symptoms of backing delamination early in the manufacturing process is critical to maintaining quality control. Symptoms on the production floor may include:Click to read the full article.

Residual Solvent Oos during scale-up: GMP investigation plan and CAPA

When a residual solvent OOS is identified, the situation presents specific symptoms or signals that indicate deeper issues in the manufacturing process. These might include:Click to read the full article.

Drug Crystallization in transdermal patch manufacturing: root cause mapping across materials and process

Identifying symptoms related to drug crystallization during transdermal patch manufacturing is essential for early intervention. Common signals may include:Click to read the full article.

Ivpt Failure during EU/UK market supply: GMP investigation plan and CAPA

Detection of anomalies in Ivpt processes can often present symptoms that indicate potential failures. Common symptoms include:Click to read the full article.